Summary: Thought Leader: Steve Lobel, PhD, D-ABMLI, MBA, FACB, Vice-president Global Laboratory Operations, PPD In this episode, Dr. Lobel talks about Drug-induced liver injury, also known as DILI. We'll cover what DILI is, how it is identified, and its effects on the clinical development process. At the end of this podcast, you'll learn where you can download a related white paper on this topic. Play Podcast For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.
